Lupin’s U.S. subsidiary receives USFDA tentative approval for its Pregabalin Capsules

07 Jul 2011 Evaluate

Pharma Major, Lupin’s U.S. subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the United States Food and Drugs Administration (USFDA’s) for the Company’s Abbreviated New Drug Application (ANDA) to market a generic version of C.P. Pharmaceuticals C.V., LYRICA (Pregabalin) capsules.

Lupin’s Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg are the AB-rated generic equivalent of LYRICA capsules, which is indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.

LYRICA capsules had annual U.S sales of approximately $1.7 billion for the twelve months ending March 2011, based on IMS Health sales data.

Lupin Share Price

2078.05 -34.90 (-1.65%)
29-Dec-2025 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.30
Dr. Reddys Lab 1268.00
Cipla 1493.10
Zydus Lifesciences 904.25
Lupin 2078.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×